lch
发布于 2026-03-23 / 0 阅读
0

Blueprint Unveiled: The 1st CPIC to Build China’s Answer to the J.P. Morgan Healthcare Conference


The 1st China Pharmaceutical Innovation Conference (CPIC), organized by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).


Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of “China Innovation – Global Translation – Shanghai as a Global Deal-Making Hub.”


This conference is not only a showcase of cutting-edge technologies, but also a strategic platform dedicated to reinforcing the biopharmaceutical sector as a national pillar industry and accelerating the global expansion of China’s innovative drugs.


The event will drive the deep integration of innovation and capital markets, highlight China’s R&D advantage and execution speed, expand global collaboration networks, and significantly enhance the international influence of Chinese innovative therapeutics.


Thousands of global industry leaders will gather in Hongqiao, Shanghai, including representatives from regulatory authorities, multinational pharmaceutical companies, leading research institutions, top biotech firms, international investment banks, professional investors, commercial banks, stock exchanges, and leading law and accounting firms.


Participants will engage in 300+ high-impact sessions and high-frequency 1-on-1 partnering meetings, jointly shaping the future landscape of China’s innovative drugs and medical devices.


As the premier gateway for global capital and enterprises to understand China’s innovation ecosystem, and a core hub for Chinese pharmaceutical companies going global, CPIC is set to become a key barometer for annual investment and collaboration in the global healthcare industry.


The official conference website, registration system, and 1-on-1 partnering platform will be launched soon. Stay tuned.




// Conference Structure //



CPIC Plenary Sessions

✓ Biopharmaceuticals as China’s Emerging Pillar Industry

✓ Global Frontiers in Biopharmaceutical Innovation

✓ The Globalization Path of Chinese Pharma

✓ First-in-Class (FIC) and World-Class Drug Development

✓ China’s R&D Advantage and Execution Speed

✓ CPIC Achievement Releases

✓ CPIC Awards Ceremony



Frontier Technologies in Innovative Drug Development

✓ CNS Drug Innovation Conference

✓ Cell Therapy & ATMP Conference

✓ In Vivo CAR-T Innovation Forum

✓ Gene Therapy & Rare Disease Drug Development Conference

✓ RNA Therapeutics Conference

✓ mRNA & Vaccine Conference

✓ T-cell Engagers & Next-Generation Antibody Therapeutics

✓ Stem Cell & Regenerative Medicine Technologies

✓ Conjugate Therapeutics Conference

✓ Novel Molecular Entities (NME) Development Conference

✓ Molecular Glues & PROTACs Conference

✓ Organoids & Biochips Conference

✓ Radiopharmaceuticals & Nuclear Medicine Innovation

✓ GLP-1 & Anti-Obesity Drug Development

✓ Biosimilar Development

✓ AI-Driven Drug Discovery Conference



Regulatory Affairs & Policy

✓ US & EU Regulatory Trends in Drug Approval

✓ China Regulatory Policy No. 818: Translational Pathways for ✓ Biomedical Innovations

✓ China Regulatory Policy No. 828: Accelerating Drug Registration

✓ China–US Drug Registration Compliance

✓ Global Regulatory Frameworks for Medical Devices



Intellectual Property & Legal

✓ IP Strategy in Biopharmaceuticals

✓ Legal Considerations for Global Expansion

✓ Cross-border Transactions & Dispute Resolution



Manufacturing & Supply Chain

✓ Modular Biopharmaceutical Manufacturing

✓ Digital Factories & Smart Manufacturing

✓ Upstream Supply Chain for Biologics

✓ Bioprocessing & Purification

✓ Cold Chain Logistics Management



MedTech & Medical Innovation

✓ Brain-Computer Interface Forum

✓ Academic & Hospital Leadership Forum

✓ Innovative Medical Devices Conference

✓ Biomedical Materials Development



China Innovation Ecosystem & Models

✓ Transformation of Traditional Pharma

✓ Biopharma Industrial Park Ecosystem Development

✓ Tech Transfer & Early-Stage Incubation

✓ Evolution of CRO/CDMO

✓ Leveraging External Partnerships to Accelerate Innovation

✓ From R&D Story to Commercial Success

✓ ESG in Biopharma



Investment, IPO & M&A

✓ IPO Pathways & Regulatory Considerations

✓ Cross-border Financing & USD Fund Strategies

✓ The Rise and Evolution of NewCo Models

✓ Real-World Assets (RWA) as Emerging Financing Tools

✓ Banking & Structured Financing for Biopharma Innovation

✓ M&A in Biopharma

✓ Project Roadshow Sessions



Global Expansion & Cross-border Collaboration

✓ Global BD Strategies and Ecosystem Evolution

✓ Global Branding, Market Access, and Commercial Strategy

✓ Global Commercialization Strategies for Innovative Drugs

✓ Southeast Asia Focus Forum

✓ China–Singapore Collaboration Forum

✓ Hong Kong as a Global Opportunity Hub

✓ China–Europe Collaboration Forum

✓ China–Japan Collaboration Forum

✓ China–Korea Collaboration Forum



Talent & Organizational Development

✓ Building BD Teams & Global Expansion

✓ Talent Strategy & Organizational Development

✓ Scientist Entrepreneurship Forum

✓ Investor-led Entrepreneurship Forum



Corporate-Branded Sessions

 1-on-1 Partnering Meetings



Social & Networking Events

✓ TONACEA Night

✓ Networking Reception

✓ Themed Luncheons

✓ Art & Aesthetic Salon

✓ 10km City Run

✓ Golf Event

✓ Networking Card Games

✓ Biopharma Park Visits

✓ Post-conference Tours for International Guests

And more…




// About TONACEA //



TONACEA is a premier ecosystem platform in China's biopharmaceutical innovation sector. With over 20 years of deep commitment to advancing China's novel drug development, it has evolved into a key organizational force driving the country's pharmaceutical innovation, serving as a core hub connecting multinational pharmaceutical companies with local innovation.


TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing ecosystem that spans the entire R&D value chain. Its business scope encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With branches in Beijing, Shanghai, Suzhou, Guangzhou, Shenzhen, and other cities, TONACEA has built a nationwide operational network.


The TONACEA WeChat official account and video channel consistently deliver in-depth industry insights, with its perspectives frequently cited by investors and media, earning recognition as a trusted "authoritative source" within the industry. The "Huashan Award," co-launched by the platform, sets a benchmark for the globalization of Chinese innovative drugs and empowers local enterprises to step onto the world stage.






// Speakers & Roadshow Presenters //



Presentation: 20 minutes

Roadshow: 15 minutes







// Session Organizers & Roundtable Hosts //



Duration: approximately 40 minutesOpen call for discussion topics and session conveners.







/Exhibitors & Partners//



A 10,000 sqm professional exhibition hall will be dedicated to brand showcases and innovation displays.







Links Related to The 1st China Pharmaceutical Innovation Conference (CPIC)

港股IPO,红筹架构的“守与破”

朱迅:中国创新药,该从“研发故事”切换到“盈利故事”了

定档7.22-24,首届大国新药全球会议(CPIC)定位“四叶草”

当银行的钱,涌入创新药

大国新药必将成就新药大国